For patients currently in compounded GLP-1 programs, the transition would likely involve one of several options: switching to an FDA-approved branded medication (at substantially higher cost), discussing alternative weight management approaches with a licensed provider, or exploring whether 503A patient-specific compounding applies to their individual clinical situation
Ratings are not available for new plans or plans with low enrollment
Gottesmann, C., Gandolfo, G., Zouikr, I., & Lachapelle, F
Clinical Trial Results: Weight Loss & Key Outcomes Phase 2 (Published in NEJM & Nature Medicine) Obesity trial (NEJM 2023): Up to 24.2% mean weight loss at 48 weeks (12 mg dose)
A patient with lower receptor sensitivity might need a higher dose to feel appetite suppression, while someone with higher sensitivity might thrive on a microdose
Key points to consider when interpreting the evidence: Most studies are short-term , typically lasting fewer than 12 weeks, making it difficult to assess long-term efficacy or safety Results appear more pronounced in older adults or individuals with obesity, compared to younger, healthy populations L-carnitine alone, without dietary or lifestyle changes , is unlikely to produce clinically meaningful weight loss Neither NICE nor the NHS recommends L-carnitine supplementation as part of any weight management pathway